HOME >> BIOLOGY >> NEWS
Long-Standing Puzzle Of Immune System Is Solved By UCSF Researchers

Researchers at the University of California San Francisco have solved a decades-long scientific puzzle about how the body's immune system works to combat illness.

In a study also having implications for better understanding cancer, the researchers found that the immune system is able to target virtually any unwanted microscopic invader within the body by subverting the function of an enzyme that normally is used to repair mistakes -- called mutations -- in the genetic material, DNA.

Immunology researchers have long suspected that immune cells take advantage of mutations that arise in genes to generate greater diversity in the genes that encode antibodies, proteins that mark disease agents for destruction. This diversity provides the immune system with a better selection from which to choose the best weapons for fighting disease.

Immunologists previously unearthed evidence indicating that immune cells can even activate mechanisms for producing additional mutations, a process dubbed hypermutation. But until now, none of the key molecular players used by immune cells to generate these mutations had been identified.

The study, co-authored by Mattias Wabl, PhD, professor of microbiology and immunology at UCSF and his laboratory team, is reported in the February 20 issue of Science.

"While mutations are, in general, harmful and unwanted, there is an important exception," Wabl explains. "B cells of the immune system depend on mutations in order to be ready to defend the body against newly arising pathogenic microorganisms.

"Without hypermutation at the immunoglobulin genes, which encode antibodies, we would likely have succumbed to an Andromeda strain long ago," Wabl says, referring to a popular science fiction thriller starring a newly arising microscopic scourge that threatens human life on Earth.

The cellular agent identified by the UCSF researchers as the one used by B c
'"/>

Contact: UCSF News Office
415-476-2557
University of California - San Francisco
20-Feb-1998


Page: 1 2 3 4

Related biology news :

1. Comprehensive Nutritional Status In Patients With Long-Standing Crohn Disease Currently In Remission
2. Puzzle solved on how influenza builds its infectious seeds
3. CAK Activation Of Plant Cell Cycle: Scientists Find Another Piece In The Jigsaw Puzzle To Help Explain Why Plants Do Not Develop Cancer Spontaneously
4. New Finding Suggests "HATs" Are Key To Gene Activation Puzzle
5. Immune systems attack dogs kept on genetic leash
6. Immune system drug may increase availability of liver transplants
7. Immune cells may help deliver cancer vaccines for children
8. Immune response depends on key molecule: Research
9. Applied Biosystems and Immune Tolerance Network announce immunology research agreement
10. Immune system component found common to both humans and worms
11. Immune cells SLAP internal signals together

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... Research and Markets has announced the addition of the ... offering. ... report provides separate comprehensive analytics for the US, Japan ... Annual estimates and forecasts are provided for the period 2015 through ... Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) ... oral peptide drug candidates, PTG-100 and PTG-200, at ... Crohn,s and Colitis Organization (ECCO).  The ECCO congress ... from February 15 – 18, 2017. ... on Protagonist drug candidates PTG-100 and PTG-200. PTG-100, ...
(Date:2/16/2017)... BEACH, Fla. , Feb. 16, 2017 /PRNewswire/ ... company revolutionizing the development of liquid biopsy tests ... has entered into an exclusive license agreement with ... distribute MDNA,s proprietary liquid biopsy test for prostate ... South Korea . This is the ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
Breaking Biology Technology:
Cached News: